Post-effective Amendment to an S-8 Filing (s-8 Pos)
05 March 2021 - 9:14AM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on March 4, 2021.
Registration No. 333-227717
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE
AMENDMENT NO. 1 TO
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
CELLECTIS S.A.
(Exact
name of registrant as specified in its charter)
|
|
|
France
|
|
Not applicable
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
Cellectis S.A.
8, rue de la Croix Jarry
75013 Paris, France
+33
1 81 69 16 00
(Address, including zip code, and telephone number, including area code, of registrants principal executive
offices)
2018 Stock Option Plan
BSA Plan
Second Free
Share 2018 Plan
(Full title of the plans)
Cellectis, Inc.
430
East 29th Street
New York, New York 10016
(347) 908-5980
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
|
|
|
|
|
Peter E. Devlin
|
|
Renaud Bonnet
|
|
Marie-Bleuenn Terrier
|
Jones Day
|
|
Jones Day
|
|
General Counsel
|
250 Vesey Street
|
|
2, rue Saint-Florentin
|
|
Cellectis S.A.
|
New York, NY 10281
|
|
75001 Paris, France
|
|
8, rue de la Croix Jarry
|
(212) 326-3939
|
|
+33 1 5659-3939
|
|
75013 Paris, France
|
|
|
|
|
+33 1 81 69 16 00
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☒
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☐
|
|
Smaller reporting company
|
|
☐
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
Cellectis S.A. (the Company) hereby amends its Registration Statement on Form S-8
(Registration No. 333-227717) (the Registration Statement) by filing this Post-Effective Amendment No. 1 to such Registration Statement (the
Post-Effective Amendment) to reflect that 400,000 of the Companys ordinary shares, 0.05 nominal value per share (Ordinary Shares) that are covered by the Registration
Statement (the Rollover Shares) are no longer issuable pursuant to the Companys BSA Plan. The Rollover Shares have instead become authorized for issuance under the Companys Second Free Share 2018 Plan. No
additional securities are being registered by this Post-Effective Amendment.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the
provisions of Rule 428 under the Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8
will be delivered to the participants in the plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
ITEM 3.
|
INCORPORATION OF DOCUMENTS BY REFERENCE
|
The following documents filed by Cellectis S.A. (the Registrant) with the U.S. Securities and Exchange Commission (the
Commission) are incorporated by reference into this Registration Statement:
(a) The Registrants annual report on Form
20-F for the fiscal year ended December 31, 2020, filed with the Commission pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange
Act) on March 4, 2021 (File No. 001-36891), which contains audited financial statements for the Registrants latest fiscal year for which such statements have been filed; and
(b) The description of the Registrants Ordinary Shares and American Depositary Shares contained in the Registrants Registration Statement on
Form 8-A filed on March 23, 2015 (File No. 001-36891) under
the Exchange Act, including any amendment or report filed for the purpose of updating such description.
All other reports and documents subsequently
filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that
all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and
documents; provided, however, that documents or information deemed to have been furnished (except for documents or information deemed to have been specifically incorporated by reference as discussed in (b) above) and not filed in accordance
with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or
superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such
statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
ITEM 4.
|
DESCRIPTION OF SECURITIES
|
Not applicable.
ITEM 5.
|
INTERESTS OF NAMED EXPERTS AND COUNSEL
|
Not applicable.
ITEM 6.
|
INDEMNIFICATION OF DIRECTORS AND OFFICERS
|
Under French law, provisions of By-laws that limit the liability of directors and officers are prohibited. However,
French law allows sociétés anonymes to contract for and maintain liability insurance against civil liabilities incurred by any of their directors and officers involved in a third-party action, provided that they acted in good
faith and within their capacities as directors or officers of the company. Criminal liability cannot be indemnified under French law, whether directly by a company or through liability insurance.
We maintain customary liability insurance coverage for our directors and executive officers, including insurance against liability under the Securities Act,
and we may enter into agreements in the future with our directors and executive officers to provide contractual indemnification. With certain exceptions and subject to limitations on indemnification under French law, these agreements would provide
for indemnification for damages and expenses including, among other things, attorneys fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding arising out of his or her actions in that
capacity.
These indemnification arrangements may discourage shareholders from bringing a lawsuit against our directors and
executive officers for breach of their fiduciary duty. These arrangements also may have the effect of reducing the likelihood of derivative litigation against directors and executive officers, even though such an action, if successful, might
otherwise benefit us and our shareholders. Furthermore, a shareholders investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification
arrangements.
Certain of our non-employee directors may, through their relationships with their employers or
partnerships, be insured against certain liabilities in their capacity as members of our board of directors.
ITEM 7.
|
EXEMPTION FROM REGISTRATION CLAIMED
|
Not applicable.
See the Exhibit Index on the page immediately preceding the signature page for a list of exhibits filed as part of this Registration Statement, which Exhibit
Index is incorporated herein by reference.
1.
|
The undersigned Registrant hereby undertakes:
|
(a) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i) To include any prospectus required by section 10(a)(3) of the Securities Act;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the
total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to
Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table in the effective Registration Statement.
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material
change to such information in the Registration Statement;
Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required
to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in
the Registration Statement.
(b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be
deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the
offering.
2.
|
The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the
Securities Act, each filing of the Registrants annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plans annual report pursuant to
Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.
|
3.
|
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in
|
|
the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid
by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue.
|
EXHIBIT INDEX
*
|
Previously filed as an exhibit to the Registration Statement on Form
S-8 (File No. 333-227717), filed with the Securities and Exchange Commission on October 5, 2018, and incorporated herein by reference.
|
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
in Paris, France on March 4, 2021.
|
|
|
CELLECTIS S.A.
|
|
|
By:
|
|
/s/ André Choulika
|
|
|
André Choulika
|
|
|
Chief Executive Officer
|
POWER OF ATTORNEY
I, the undersigned director, hereby constitute and appoint Dr. André Choulika and Marie-Bleuenn Terrier, and each of them singly, my true and
lawful attorneys, with full power to any of them, and to each of them singly, to sign for me and in my names in the capacity indicated below the post-effective amendment to the registration statement on Form
S-8 filed herewith, and any and all subsequent post-effective amendments to said registration statement, under the Securities Act of 1933, as amended, in connection with the registration under the Securities
Act of 1933, as amended, of equity securities of Cellectis S.A., and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of them might or could do in person, and
hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.
Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the
following persons in the capacities indicated on March 4, 2021.
|
|
|
|
|
Signature
|
|
Title
|
|
|
|
|
|
/s/ Jean-Pierre Garnier
Jean-Pierre Garnier
|
|
Chairman of the Board
|
|
|
Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the
Registration Statement has been signed by the following persons in the capacities indicated on March 4, 2021.
|
|
|
|
|
Signature
|
|
Title
|
|
|
|
|
|
/s/ André Choulika
André Choulika
|
|
Chief Executive Officer, Director and Co-Founder
(Principal Executive Officer)
|
|
|
|
|
|
*
Eric Dutang
|
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
*
David Sourdive
|
|
Director, Executive Vice President Technical Operations and Co-Founder
|
|
|
|
|
|
*
Laurent Arthaud
|
|
Director
|
|
|
|
|
|
*
Pierre Bastid
|
|
Director
|
|
|
|
|
|
*
Rainer Boehm
|
|
Director
|
|
|
|
|
|
*
Alain Godard
|
|
Director
|
|
|
|
|
|
*
Hervé Hoppenot
|
|
Director
|
|
|
|
|
|
*
Annick Schwebig
|
|
Director
|
|
|
|
|
|
Cellectis, Inc., Authorized Representative in the United States
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ André Choulika
|
|
|
|
|
André Choulika
|
|
|
|
|
President
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*By:
|
|
/s/ Marie-Bleuenn Terrier
|
|
Attorney-in-Fact
|
|
|
|
|
Marie-Bleuenn Terrier
|
|
|
|
|
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Jul 2023 to Jul 2024